Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.

When standard therapies fail in chronic lymphocytic leukemia (CLL), two evolving strategies are gaining traction: CAR T-cell therapy bridged with pirtobrutinib, and a pirtobrutinib-venetoclax-rituximab triplet at relapse. Real-world data look promising, but prospective trials are still needed. Experts say fit patients with high-risk or bulky disease may be the best candidates for these approaches.
For patients with chronic lymphocytic leukemia (CLL) who've exhausted both BTK inhibitors and venetoclax, options have historically been slim. But two emerging strategies are reshaping the landscape for this tough-to-treat population.
Lisocabtagene maraleucel — the only CAR T-cell therapy approved in CLL — is showing improved outcomes when paired with ibrutinib. Clinicians are increasingly using pirtobrutinib as a "bridge" therapy to shrink tumor bulk before CAR T infusion, and even continuing it alongside CAR T treatment. Real-world results look numerically favorable, though experts stress that prospective trials are still needed to confirm the benefit. Separately, adding pirtobrutinib to the venetoclax-rituximab combo at relapse has shown improved progression-free survival, even in patients previously exposed to covalent BTK inhibitors.
Key Takeaways:
Why it matters: These strategies offer new hope for CLL patients who've run out of standard options, but careful patient selection — favoring fit individuals with high-risk features or bulky disease seeking fixed-duration therapy — will be critical as the field awaits regulatory approval and longer-term data.